27 Dec, 11:44 - Indian

SENSEX 78823.27 (0.45)

Nifty 50 23860.94921875 (0.47)

Nifty Bank 51390.3515625 (0.43)

Nifty IT 43621.1484375 (-0.10)

Nifty Midcap 100 57085.8984375 (-0.07)

Nifty Next 50 68990.046875 (-0.25)

Nifty Pharma 22942.19921875 (1.01)

Nifty Smallcap 100 18755.80078125 (0.14)

27 Dec, 11:44 - Global

NIKKEI 225 40274.45 (1.79)

HANG SENG 20082.59 (-0.08)

S&P 6091.5 (-0.26)

Login/Signup
LOGIN HERE
Cancel

Solara Active Pharma Sciences Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 541540 | NSE Symbol : SOLARA | ISIN : INE624Z01016 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
14-Oct-2024 21-Oct-2024 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2024 and other matters SOLARA : Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 Equity shares pursuant to exercise of ESOP Grant under SOLARA ESOP Plan ,2018. Read less.. Solara Active pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 equity shares pursuant to exercise of ESOP granted under SOLARA ESOP Plan 2018 Read less.. (As Per BSE Announcement Dated on 21.10.2024)
15-Jul-2024 22-Jul-2024 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2024 inter alia to consider and approve unaudited financial results for the quarter ended June 30 2024. Unaudited financial results for the quarter ended June 30, 2024 (As per BSE Announcement Dated on 22/07/2024)
21-May-2024 29-May-2024 Accounts Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31 2024. Results for the period ended March 31, 2024 Outcome of Board Meeting (As Per BSE Announcement Dated on 29.05.2024)
05-Feb-2024 14-Feb-2024 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve unaudited financial results for the period ended December 31 2023 Unaudited Financial Results for the period ended December 31, 2023 Resignation of Mr. P V Raghavendra Rao from the position of Chief Financial Officer of the Company from the close of business hours of February 15, 2024. Appointment of Mr. M Mohan as Executive Director of the Company with effect from February 14, 2024. (As Per BSE Announcement Dated on 14/02/2024)
07-Nov-2023 14-Nov-2023 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve unaudited Financial Results for the period ended September 30 2023. Unaudited Financial Results for the quarter ended September 30, 2023 We hereby inform you that based on the recommendations of the Nomination & Remuneration Committee, the Board of Directors of the Company has appointed Mr. Rajendra Kumar Srivastava as Additional Non-Executive Independent Director and Mr. Rajiv Vijay Nabar as Additional Non- Executive Non-Independent Director of the Company with effect from November 14, 2023. (As per BSE Announcement Dated on 14/11/2023)
19-Oct-2023 19-Oct-2023 Change in Other Executives In accordance with SEBI (LODR), Regulations, 2015, it is hereby informed that the Board in its meeting held today has approved the appointment of Mr. P.V Raghavendra Rao as Chief Financial Officer of the Company and designated him as KMP with effect from October 26, 2023.
04-Aug-2023 14-Aug-2023 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30 2023 amongst other matters. The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023 The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023 (As per BSE Announcement Dated on 07/08/2023) Pursuant to Regulation 30 of SEBI (LODR), this is to inform you that Board of Directors at their meeting held today (August 14, 2023) have approved and reconstituted the composition of Audit Committee, Risk Mangement Committee and Corporate Social Responsibility Committee. (As Per BSE Announcement Dated on 14.08.2023)
30-Jun-2023 05-Jul-2023 Right Issue Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/07/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations) this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday July 5 2023 inter alia to consider the proposal to issue equity shares to existing shareholders on Rights basis as may be permitted under applicable law subject to such regulatory/statutory approvals as may be required. SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed BSE about Board Meeting to be held on 05 Jul 2023 to consider Fund raising. (As Per BSE Announcement Dated on 30.06.2023) 1. The offer and issuance of equity shares of face value of ?10 each of the Company (the 'Equity Shares') for an aggregate amount, including premium, not exceeding Rs. 450 Crores (Rupees Four Hundred and Fifty Crores) by way of a rights issue to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such approvals, as may be required under the applicable laws ('Rights Issue'). Pursuant to Regulation 30 of SEBI (LODR), 2015 WE wish to inform that the Board of Directors has considered and approved for issuance of equity shares to existing shareholders on Rights Basis (As Per BSE Announcement dated on 05.07.2023)
04-May-2023 12-May-2023 Accounts Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2023 inter alia to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31 2023 amongst other matters. Audited financial results (standalone and consolidated) of the Company for the quarter and Year ended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023, along with the Auditors report for the said period and press release on the same is attached. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('Listing Regulations'), we wish to inform that based on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held today, i.e. May 12, 2023, has, subject to the approval of the members of the Company to be obtained in the ensuing Annual general meeting of the Company, recommended the re-appointment of Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration Number: 117366W/W-100018) as the Statutory Auditors of the Company under Section 139 of the Companies Act 2013. (As Per BSE Announcement Dated on 12/05/2023)
19-Jan-2023 25-Jan-2023 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 inter alia to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2022 amongst other matters. Unaudited financial results (standalone and consolidated) of the Company for the quarter ended December 31, 2022. A copy of the unaudited financial results (standalone and consolidated) for the quarter ended December 31, 2022, along with the Limited Review Report by the Auditors and press release is attached. Outcome of Board Meeting held on January 25, 2023 Pursuant to Regulation 30 read with Part A, Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), we wish to inform you that the Board of Directors of the Company has appointed Mr. Poorvank Purohit as Chief Executive Officer and as Key Managerial Personnel (KMP) with effect from February 3, 2023. (As per BSE Announcement Dated on 25/01/2023)
02-Nov-2022 09-Nov-2022 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2022 amongst other matters. We wish to inform that meeting of Board of Directors of the company held today (i.e., November 9, 2022), the Directors has inter-alia approved Unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the unaudited financial results (standalone and consolidated) along with the Limited Review Report by the Auditors and press release is attached. (As Per BSE Announcement Dated on 09/11/2022)
28-Jul-2022 04-Aug-2022 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 inter alia to consider and approve We wish to inform the Exchange about Board Meeting to be held on 04-Aug-2022 to consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2022. Unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2022, along with the Limited Review Report by the Auditors and press release is attached. (As Per BSE Announcement Dated 04.08.2022)
22-Apr-2022 29-Apr-2022 Accounts Audited Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2022 ,inter alia, to consider and approve This is in continuation to our earlier intimation dated April 22, 2022, with respect to the ensuing meeting of the Board of Directors of the Company, scheduled on April 29, 2022. In terms of Regulation 29 of the SEBI Listing Regulations, we wish to inform that the Board of Directors, at its meeting scheduled to be held on Friday, April 29, 2022, shall also consider and recommend Dividend, if any, for the financial year 2021-22. With reference to the earlier intimation dated April 22, 2022, with respect to the ensuing meeting of the Board of Directors of the Company, scheduled on April 29, 2022. Solara Active Pharma Sciences Ltd has now informed BSE that the Board of Directors, at its meeting scheduled to be held on April 29, 2022, shall also consider and recommend Dividend, if any, for the financial year 2021-22. (As Per BSE Announcement Dated on 26.04.2022) Audited financial results (standalone and consolidated) of the Company for the quarter andYear ended March 31, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations andDisclosure Requirements) Regulation, 2015. A copy of the audited financial results(standalone and consolidated) for the quarter and year ended March 31, 2022 along with the Auditors report for the said period and press release on the same is attached Intimation for withdrawal of the Composite Scheme of Amalgamation We wish to inform you that Mr. Rajender Rao Juvvadi has resigned from the position of Managing director and CEO and directorship of the company with effect from April 28, 2022. Kindly take the same on record We wish to inform that Mr. Jitesh Devendra has been appointed as Managing Director of the company with effect from April 29, 2022. (As Per BSE Announcement Dated on 29.04.2022)
09-Mar-2022 09-Mar-2022 Change in Other Executives We wish to inform you that the Board of Directors of the Company has taken on record/approved the Resignation of Mr. Subhash Anand as Executive director and Chief Financial Officer and Appointment of Mr. S. Hariharan as Chief Financial Officer of the company at its meeting held on March 9, 2022. We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited held today (i.e., March 9, 2022), the Board has approved the allotment of 30,000 equity shares against the Solara Employee Stock Option Plan 2018.
31-Jan-2022 09-Feb-2022 Quarterly Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday February 9 2022 to inter alia consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months period ended December 31 2021 amongst other matters. Financial results for the period ended december 31st, 2021 We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited ('Company') held today (i.e., February 9, 2022), the Board has approved the allotment of 20,000 equity shares against the Solara Employee Stock Option Plan 2018. (As per BSE Announcement Dated on 09/02/2022) Please find enclosed copies of the newspaper advertisement titled ''Consolidated unaudited financial results for quarter and nine months ended December 31, 2021''. The advertisements appeared in Business Standard and Lokmat (Marathi version). (As Per BSE Announcement Dated 14.02.2022)
1 2